About MicrobeDx
MicrobeDx is a company based in Los Angeles (United States) founded in 2015. MicrobeDx has raised $6.21 million across 5 funding rounds from investors including HHS. MicrobeDx operates in a competitive market with competitors including Cepheid, Biological Dynamics, Karius, Day Zero Diagnostics and OpGen, among others.
- Headquarter Los Angeles, United States
- SectorsHealthcare
- Email••••••••
- Website microbedx.com
- Social LinkedIn
- Total Equity Funding$6.21M (USD)
in 5 rounds
- Latest Funding Round$300K (USD), Series A
Dec 2020
- Investors
Funding Insights of MicrobeDx
MicrobeDx has successfully raised a total of $6.21M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $300 thousand completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.21M
- Total Rounds 5
- Last Round Series A — $300,000
- First Round $400,000
(May 2017)
- Investors Count 1
All 5 funding rounds of MicrobeDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $300,000 | Series A | – | – | – |
| Mar 2019 | $3.01M | Series A | – | – | – |
| Mar 2018 | $300,000 | Grant | – | – | |
| Jan 2018 | $2.5M | Series A | – | – | – |
| May 2017 | $400,000 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in MicrobeDx
MicrobeDx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for MicrobeDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MicrobeDx
2 people are tracked at MicrobeDx (2 in leadership).
| Name | Role | Group |
|---|---|---|
Bernard Churchill | CEO | Leadership |
Colin Halford | Co-founder & Chief Scientific Officer | Leadership |
Complete people profiles for MicrobeDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MicrobeDx
3 dated milestones of MicrobeDx across 5 years, from founding to its latest funding, stage changes and deals.
- Founded MicrobeDx is founded.
- Funding First funding round of $400K.
- Funding Latest funding round, Series A, of $300K.
Competitors of MicrobeDx
MicrobeDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, Biological Dynamics, Karius, Day Zero Diagnostics and OpGen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cepheid.com | 1996 | Sunnyvale, United States | $19.1M | 1,299 | Developer of molecular diagnostic testing solutions | |
| biologicaldynamics.com | 2010 | San Diego, United States | $67.65M | 54 | Proprietary lab-on-chip platform for nanoparticle isolation is offered. | |
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| dayzerodiagnostics.com | 2016 | Boston, United States | $48.6M | 48 | Genome sequencing diagnostics for infectious diseases are developed. | |
| opgen.com | 2002 | Rockville, United States | $77.51M | 100 | Developer of diagnostics and bioinformatics platforms for providers | |
| clearlabs.com | 2014 | Menlo Park, United States | $171.09M | 55 | Food safety technologies are provided for pathogen identification. | |
| oxfordimmunotec.com | 2002 | Abingdon, United Kingdom | $94M | 184 | Immune markers are utilized by Oxford Immunotec for disease diagnostics. | |
| seluxdx.com | 2014 | Cambridge, United States | $161.01M | – | Developer of alternatives to traditional ELISA assays | |
| springbankpharm.com | 2002 | Milford, United States | $36.7M | 84 | Viral infection treatments are developed using nucleic acid hybrid chemistry. |
Detailed competitors of MicrobeDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Microbedx
Complete news archive for MicrobeDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to MicrobeDx
10 companies that operate in the same segment as MicrobeDx (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MicrobeDx
MicrobeDx was founded in 2015 and raised its 1st funding round 2 years after it was founded.
MicrobeDx is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
MicrobeDx is a funded company, having raised a total of $6.21M across 5 funding rounds to date. The company's 1st funding round was a Seed of $400K, raised on May 2017.
MicrobeDx was founded in 2015 and is headquartered in Los Angeles, United States, operating in the biotechnology sector focused on diagnostic tools. A platform is developed by the company that employs hybridization and capture of ribosomal RNA for bacterial species identification without PCR, integrated with phenotypic testing for antibiotic susceptibility. Results for species identification are achieved in 30-45 minutes, while susceptibility testing is completed within 3 hours.
MicrobeDx's top competitors include Cepheid, Clear Labs and Day Zero Diagnostics.
MicrobeDx has 1 investor. Key investors include HHS.